MENU
+Compare
SUPN
Stock ticker: NASDAQ
AS OF
Apr 17 closing price
Price
$30.76
Change
+$0.05 (+0.16%)
Capitalization
1.84B

SUPN Supernus Pharmaceuticals Forecast, Technical & Fundamental Analysis

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company... Show more

SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SUPN with price predictions
Apr 17, 2025

SUPN sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for SUPN moved below the 200-day moving average on April 14, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SUPN as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SUPN turned negative on April 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SUPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.992) is normal, around the industry mean (60.843). SUPN's P/E Ratio (1677.000) is considerably higher than the industry average of (89.540). SUPN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.913). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (3.065) is also within normal values, averaging (20.019).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SUPN is expected to report earnings to rise 38.26% to 37 cents per share on May 13

Supernus Pharmaceuticals SUPN Stock Earnings Reports
Q1'25
Est.
$0.37
Q4'24
Missed
by $0.06
Q3'24
Beat
by $0.25
Q2'24
Beat
by $0.37
Q1'24
Missed
by $0.38
The last earnings report on February 25 showed earnings per share of 27 cents, missing the estimate of 33 cents. With 476.31K shares outstanding, the current market capitalization sits at 1.84B.
A.I. Advisor
published General Information

General Information

a developer for the treatment of central nervous system

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
9715 Key West Avenue
Phone
+1 301 838-2500
Employees
652
Web
https://www.supernus.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

SUPN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with DVAX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then DVAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
+0.16%
DVAX - SUPN
34%
Loosely correlated
-3.19%
AQST - SUPN
26%
Poorly correlated
+0.40%
COLL - SUPN
25%
Poorly correlated
-0.04%
ALKS - SUPN
24%
Poorly correlated
-0.74%
ETON - SUPN
24%
Poorly correlated
+1.85%
More